The condition of hemorheology and hemodynamics has been studied in patients with exertional angina (n = 20) and with effort angina presenting with concomitant chronic persisting hepatitis (n = 25). Coronary patients presenting with concurrent abnormalities of the hepatobiliary system displayed a significant reduction in the hepatic bloodflow resultant from a long-duration disorder of the liver and association of disturbances in the central hemodynamics and local autoregulatory mechanisms of compensation for intraorganic circulation.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Systemic lupus erythematosus and pulmonary tuberculosis in a patient developing acute-onset type 1 diabetes.
Diabetol Int
January 2025
Department of Endocrinology and Diabetes, NTT Medical Center Tokyo, 141-86255-9-22 Higashi-Gotanda, Shinagawa-ku, Tokyo Japan.
A 73-year-old Japanese woman was admitted to our hospital with anorexia, weight loss, and fever. A few weeks prior to admission, she became aware of anorexia. She was leukopenic, complement-depleted, and positive for antinuclear antibodies and anti-double stranded DNA antibodies.
View Article and Find Full Text PDFRationale and design of the FAIR-HF2-DZHK05 trial: Ferric carboxymaltose assessment of morbidity and mortality in patients with iron deficiency and chronic heart failure.
Eur J Heart Fail
January 2025
Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Aims: While it is widely accepted that intravenous (IV) iron improves functional capacity, symptoms, and cardiovascular outcomes in patients with heart failure (HF) with reduced ejection fraction (HFrEF) diagnosed with iron deficiency (ID), three recently published cardiovascular outcome trials (AFFIRM-AHF, IRONMAN and HEART-FID) of IV iron supplementation in HF failed to demonstrate a significant benefit on their respective primary endpoints. Dosing of IV iron after the initial correction of baseline ID - by design or as a result of trial circumstances - was relatively low (i.e.
View Article and Find Full Text PDFThe complexities of elexacaftor/tezacaftor/ivacaftor therapeutic drug monitoring in a person with cystic fibrosis and pulmonary disease.
Eur Clin Respir J
January 2025
Adult Cystic Fibrosis Centre, The Prince Charles Hospital, Brisbane, Queensland, Australia.
Therapeutic drug monitoring (TDM) of elexacaftor/tezacaftor/ivacaftor (ETI) remains challenging due to a lack of clarity around the parameters that govern ETI plasma concentrations, whilst the use of concomitant CYP3A inducers rifabutin and rifampicin is not recommended. We present the complexities of TDM for ETI performed in a person with cystic fibrosis and refractory pulmonary disease. Utilising National Association of Testing Authorities (NATA) accredited assays and target considerations published by the Therapeutic Goods Administration (TGA), Australia, ETI plasma concentration variability was monitored over the course of an acute admission with added complexity from an antibiotic regimen including rifabutin, a moderate cytochrome P450 3A (CYP3A) inducer, and clofazimine, a mild CYP3A inhibitor.
View Article and Find Full Text PDFConcomitant Parvovirus B19 and CMV Infection in a Child with Kidney Transplant.
Indian J Nephrol
June 2024
Department of Pediatric Nephrology, Pediatric Chronic Kidney Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Parvovirus B19 is a common human infection worldwide and is typically self-limiting in healthy persons but immunocompromised patients require specific treatments. Pretransplant B19 screening doesn't seem to be important or have any impact on the transplantation process but cytomegalovirus (CMV) study is crucial. We present a kidney-transplanted child infected by parvovirus B19 and cytomegalovirus presented with intractable anemia and raised creatinine.
View Article and Find Full Text PDFHepatitis B virus infection and metabolic dysfunction associated steatotic liver disease: Rising pandemic with complex interaction.
World J Hepatol
January 2025
Department of Medicine, Aga Khan University Hospital, Karachi 74800, Pakistan.
Due to sedentary lifestyle and rising prevalence of obesity, patients with general population and those who are infected with chronic hepatitis B are found to have metabolic dysfunction associated steatotic liver disease (MASLD). Both chronic hepatitis B virus (HBV) infection and MASLD can damage hepatocytes in their own way, but concomitant HBV-MASLD has its own clinical implications. Cherry on top is the presence of diabetes mellitus, hypertension or obesity which added more chances of unfavorable outcomes in these patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!